Expert Opinion on Biological Therapy最新文献_第8页

Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art. 使用生物制剂治疗胃癌的靶向和联合免疫疗法：最新进展。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-10-01 Epub Date: 2024-10-04 DOI: 10.1080/14712598.2024.2401622

Jane E Rogers, Qiong Gan, Rebecca E Waters, Ashley A Horak, Jaffer A Ajani

{"title":"Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art.","authors":"Jane E Rogers, Qiong Gan, Rebecca E Waters, Ashley A Horak, Jaffer A Ajani","doi":"10.1080/14712598.2024.2401622","DOIUrl":"10.1080/14712598.2024.2401622","url":null,"abstract":"Introduction: Gastric adenocarcinoma (GAC) remains a prevalent cancer worldwide and its incidence is increasing in South America. The heterogenous nature of GAC makes advances in management challenging.Areas covered: Despite challenges, recent therapeutic targets are individualizing treatment. For localized disease with microsatellite-instability-high/deficient mismatch repair, immunotherapy is now an adopted practice. In the advanced unresectable setting, those harboring human epidermal growth factor receptor-2 (HER2) expression continue to be a separate entity.Expert opinion: Future targets are developing. Among these include claudin 18.2 (CLDN18.2), fibroblast growth factor receptor 2b (FGFR2b), and trophoblast cell surface antigen-2 (TROP-2). FDA approval of zolbetuximab's, an anti-CLDN 18.2 monoclonal antibody, is expected soon. Additionally, bemarituzumab, ananti-FGFR2b monoclonal antibody, has shown improvements in combination with chemotherapy in those with HER2 negative GAC with FGFR2 overexpression. This combination is now being investigated in a phase 3 trial. Lastly, TROP-2 has emerged as an exciting solid tumor target and study is expected in GAC. All three of these therapeutic targets have seen an abundance of drug development in recent years, and we anticipate newer targeted agents driving therapeutic decisions in GAC in the coming years.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1005-1015"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The frontier of neoadjuvant therapy in non-small cell lung cancer beyond PD-(L)1 agents. 超越 PD-(L)1 药物的非小细胞肺癌新辅助疗法前沿。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-25 DOI: 10.1080/14712598.2024.2408292

Marco Sposito, Serena Eccher, Ilaria Scaglione, Alice Avancini, Antonio Rossi, Sara Pilotto, Lorenzo Belluomini

{"title":"The frontier of neoadjuvant therapy in non-small cell lung cancer beyond PD-(L)1 agents.","authors":"Marco Sposito, Serena Eccher, Ilaria Scaglione, Alice Avancini, Antonio Rossi, Sara Pilotto, Lorenzo Belluomini","doi":"10.1080/14712598.2024.2408292","DOIUrl":"10.1080/14712598.2024.2408292","url":null,"abstract":"Introduction: While surgical resection is the cornerstone of treatment for resectable lung cancer, neoadjuvant/adjuvant chemotherapy has shown limited improvement in survival rates over the past decades. With the success of immune checkpoint inhibitors (ICIs) in advanced NSCLC, there is growing interest in their application in earlier stages of the disease. Recent approvals for neoadjuvant/adjuvant ICIs in stage II-IIIA NSCLC highlight this shift in treatment paradigms.Areas covered: In this review, we aim to explore available data regarding alternative agents beyond the PD-(L)1 inhibitors, such as monoclonal antibodies against CTLA4, LAG3, TIGIT, antiangiogenic drugs, and novel therapies (antibody drug conjugates, bispecific antibodies) in neoadjuvant/perioperative regimens.Expert opinion: Novel agents and combinations (with or without ICI or/and chemotherapy), guided by molecular profiling and immune phenotyping, showed promise in improving surgical and survival outcomes. Crucial is, also in early setting, to identifying biomarkers predictive of treatment efficacy in order to personalize neoadjuvant/perioperative treatment strategies.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1025-1037"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physicians' and patients' perception of biosimilars and factors affecting biosimilar prescribing in selected Asian countries: a survey study. 选定亚洲国家医生和患者对生物仿制药的看法以及影响生物仿制药处方的因素：一项调查研究。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-17 DOI: 10.1080/14712598.2024.2400523

Supat Thongpooswan, Anupam Das, Pravin Patil, Mark Latymer, Lyndon Llamado, James Wee

{"title":"Physicians' and patients' perception of biosimilars and factors affecting biosimilar prescribing in selected Asian countries: a survey study.","authors":"Supat Thongpooswan, Anupam Das, Pravin Patil, Mark Latymer, Lyndon Llamado, James Wee","doi":"10.1080/14712598.2024.2400523","DOIUrl":"10.1080/14712598.2024.2400523","url":null,"abstract":"Background: This study evaluated physicians' and patients' beliefs about biosimilars in Hong Kong, India, Pakistan, Singapore, Taiwan, and Thailand.Research design and methods: An online survey administered to physicians (dermatologists, n = 119; gastroenterologists, n = 148; rheumatologists, n = 161) between 22 October 2021 and 7 January 2022, and patients (n = 90) with rheumatic or inflammatory bowel disease between 25 October 2021 and 12 April 2022.Results: Most (68%) physicians reported having a strong knowledge about biosimilars, yet 49% indicated that biosimilars are readily available to them. Physicians cited potential cost savings (81%) as the main benefit of biosimilars, and cost/coverage support (36%), patient support (25%), and increasing biosimilar awareness/education (24%) as main strategies for improving usage. Few (21%) patients reported having a strong knowledge about biosimilars. Patients cited offering alternatives in case of drug shortages (77%) as the main benefit of biosimilars, and cost/coverage support (53%), increasing awareness of product profile (22%), and providing biosimilars with a good efficacy profile/effective product (19%) as main strategies for improving usage.Conclusion: Programs focused on cost/coverage support, patient support, and biosimilar awareness could improve acceptance of biosimilars for chronic immune-mediated inflammatory diseases in Asian countries, thereby increasing patient access to essential biologic therapies.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1171-1182"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress. 针对小儿溃疡性结肠炎的单克隆抗体：临床进展回顾。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-20 DOI: 10.1080/14712598.2024.2404076

Debora Curci, Marianna Lucafò, Giuliana Decorti, Gabriele Stocco

{"title":"Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress.","authors":"Debora Curci, Marianna Lucafò, Giuliana Decorti, Gabriele Stocco","doi":"10.1080/14712598.2024.2404076","DOIUrl":"10.1080/14712598.2024.2404076","url":null,"abstract":"Introduction: In children, ulcerative colitis (UC) is often more severe and extensive than in adults and hospitalization for acute exacerbations occurs in around a quarter of subjects. There is a need for effective drugs, which could avoid or reduce the use of corticosteroids which, especially in children, are burdened by a number of severe side effects. The introduction in therapy of monoclonal antibodies has completely changed the therapeutic scenario and the prognosis of the disease.Areas covered: In this review, the use of the monoclonal antibodies directed against tumor necrosis factor (TNF)α or other inflammatory targets for the treatment of pediatric UC will be discussed. A search of the literature was done using the keywords 'pediatric,' 'ulcerative colitis,' 'inflammatory bowel disease,' 'monoclonal antibodies;' 'infliximab,' 'adalimumab,' 'golimumab,' vedolizumab,\" 'ustekinumab' and 'risankizumab.'Expert opinion: The use of monoclonal antibodies has greatly increased in recent years in pediatric UC, both in patients who did not respond to conventional therapies, and, more often, as initial therapy. Thanks to therapeutic drug monitoring and to the availability of biologics with different targets, therapy has become more targeted and personalized, with a significant improvement in response, in quality of life, and with a good safety profile.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1133-1144"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unmet needs in cervical cancer - can biological therapies plug the gap? 宫颈癌方面尚未满足的需求--生物疗法能否填补空白？

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-25 DOI: 10.1080/14712598.2024.2408754

Michelle Greenman, Yifan Emily Chang, Blair McNamara, Levent Mutlu, Alessandro D Santin

{"title":"Unmet needs in cervical cancer - can biological therapies plug the gap?","authors":"Michelle Greenman, Yifan Emily Chang, Blair McNamara, Levent Mutlu, Alessandro D Santin","doi":"10.1080/14712598.2024.2408754","DOIUrl":"10.1080/14712598.2024.2408754","url":null,"abstract":"Introduction: Cervical cancer remains one of the most common gynecologic malignancies worldwide. A disproportionate burden of cases occurs in developing countries due to inadequate screening and treatment. Even among patients adequately treated, in the presence of locally advanced or recurrent disease, outcomes tend to be poor. The introduction of biologic therapy into treatment has increased overall survival; however, a considerable opportunity still exists to improve current standards in treatment. Biologics have shown antitumor activity in multiple tumor types and are actively being pursued for the management of cervical cancer.Areas covered: In this article, we will discuss the historical evolution of biologic therapy in cervical cancer including use of angiogenesis inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, and vaccines. We will review how these therapies have been integrated into current treatment recommendations and discuss ongoing investigations intended to improve clinical outcomes. We also postulate on persistent gaps in care.Expert opinion: Biologic therapies have had a tremendous impact on our current approach to managing cervical cancer. We anticipate that significant more research and development will be committed to the continued investigation of biologics in cervical cancer in an effort to improve a historically difficult to treat malignancy.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"995-1003"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target. IL-23 在银屑病关节炎中的免疫学作用：潜在的治疗靶点。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1080/14712598.2024.2401148

Qin-Yi Su, Heng-Yan Gao, Yue-Ru Duan, Jing Luo, Wei-Ze Wang, Xi-Chao Qiao, Sheng-Xiao Zhang

{"title":"The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target.","authors":"Qin-Yi Su, Heng-Yan Gao, Yue-Ru Duan, Jing Luo, Wei-Ze Wang, Xi-Chao Qiao, Sheng-Xiao Zhang","doi":"10.1080/14712598.2024.2401148","DOIUrl":"10.1080/14712598.2024.2401148","url":null,"abstract":"Introduction: Psoriatic arthritis (PsA) is a debilitating chronic condition characterized by inflammation of the joints, bones, enthesis, and skin. The pivotal role of interleukin-23 (IL-23) in the pathogenesis of PsA has become increasingly evident. This proinflammatory cytokine is markedly elevated in patients with PsA, suggesting its potential as a therapeutic target. Consequently, IL-23 inhibitors have emerged as promising first-line biologic treatments for PsA.Areas covered: This review delves into the immunopathogenic mechanisms of IL-23 at the cellular and molecular levels in PsA. Furthermore, it provides the recent efficacy and safety profiles of IL-23 inhibitors. We conducted a literature search in PubMed for the following terms: 'IL-23 and psoriatic arthritis,' 'Ustekinumab,' 'Guselkumab,' 'Risankizumab,' and 'Tildrakizumab.' In addition, we retrieved clinical trials involving IL-23 inhibitors registered in ClinicalTrials.gov, EudraCT, and ICTRP.Expert opinion: Despite the promising outcomes observed with IL-23 inhibitors, several challenges persist. The long-term effects of these agents require further investigation through prospective studies, and their limited accessibility worldwide necessitates urgent attention. Additionally, ongoing research is warranted to explore other potential drug targets within the IL-23/IL-23 R axis. The development of reliable biomarkers could greatly enhance early detection, tailored management strategies, and personalized treatment approaches for patients with PsA.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1119-1132"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent developments in CD19-targeted therapies for follicular lymphoma. CD19靶向治疗滤泡性淋巴瘤的最新进展。

IF 4.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-18 DOI: 10.1080/14712598.2024.2404100

Aditi Saha,Julio C Chavez

引用次数: 0

The future of interleukin gene therapy in head and neck cancers. 白细胞介素基因疗法在头颈部癌症中的前景。

IF 4.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-18 DOI: 10.1080/14712598.2024.2405568

Cosima C Hoch,Khouloud Hachani,Yu Han,Benedikt Schmidl,Markus Wirth,Gabriele Multhoff,Ali Bashiri Dezfouli,Barbara Wollenberg

{"title":"The future of interleukin gene therapy in head and neck cancers.","authors":"Cosima C Hoch,Khouloud Hachani,Yu Han,Benedikt Schmidl,Markus Wirth,Gabriele Multhoff,Ali Bashiri Dezfouli,Barbara Wollenberg","doi":"10.1080/14712598.2024.2405568","DOIUrl":"https://doi.org/10.1080/14712598.2024.2405568","url":null,"abstract":"INTRODUCTIONHead and neck cancer (HNC), primarily head and neck squamous cell carcinomas, originates from the squamous epithelium in areas like the oral cavity, lip, larynx, and oropharynx. With high morbidity impacting critical functions, combined treatments like surgery, radiation, and chemotherapy often fall short in advanced stages, highlighting the need for innovative therapies.AREAS COVEREDThis review critically evaluates interleukin (IL) gene therapy for treating HNC. The discussion extends to key ILs in HNC, various gene therapy techniques and delivery methods. We particularly focus on the application of IL-2, IL-12, and IL-24 gene therapies, examining their mechanisms and outcomes in preclinical studies and clinical trials. The final sections address IL gene therapy challenges in HNC, exploring solutions and critically assessing future therapeutic directions.EXPERT OPINIONDespite advancements in genomic and immunotherapy, significant challenges in HNC treatment persist, primarily due to the immunosuppressive nature of the tumor microenvironment and the adverse effects of current therapies. The therapeutic efficacy of IL gene therapy hinges on overcoming these hurdles through refined delivery methods that ensure targeted, tumor-specific gene expression. Future strategies should focus on refining gene delivery methods and combining IL gene therapy with other treatments to optimize efficacy and minimize toxicity.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":"2 1","pages":"1-17"},"PeriodicalIF":4.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142266214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars 非小细胞肺癌患者的长期无进展生存期：聚焦贝伐珠单抗及其生物仿制药

IF 4.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-16 DOI: 10.1080/14712598.2024.2405562

Fran Seiwerth, Lela Bitar, Miroslav Samaržija, Marko Jakopović

引用次数: 0

Clinical experience of using biosimilars in Crohn’s disease and their effectiveness 在克罗恩病中使用生物仿制药的临床经验及其有效性

IF 4.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-13 DOI: 10.1080/14712598.2024.2401616

Léa Sequier, Bénédicte Caron, Silvio Danese, Laurent Peyrin-Biroulet

引用次数: 0